Metastatic Medullary Thyroid Carcinoma and Cabozantinib: Case Series and Review of Literature

Cabozantinib, a tyrosine kinase inhibitor, was approved by the US Food and Drug Administration in November 2012, for the treatment of metastatic medullary thyroid carcinoma. Although side effects typically include stomatitis, palmar-plantar erythrodysesthesia syndrome, hypertension and diarrhea, mos...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:World J Oncol
Main Authors: Kapur, Sakshi, Xiao, Han, Zakowski, Maureen F., Hameed, Meera R., Levin, Miles B.
Format: Artigo
Jezik:Inglês
Izdano: Elmer Press 2014
Teme:
Case Report
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC5649879/
https://ncbi.nlm.nih.gov/pubmed/29147383
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.14740/wjon779w
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki